Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

HUMAN PROTEOLYTIC BETA-AMYLOID SPECIFIC ANTIBODIES FOR TREATMENT OF ALZHEIMERS DI

Award Number: R43AG039892
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2011
PERIOD OF PERFORMANCE END DATE: 05/31/2012

Group Awards By:

View Award Description

HUMAN PROTEOLYTIC BETA-AMYLOID SPECIFIC ANTIBODIES FOR TREATMENT OF ALZHEIMERS DI - DESCRIPTION (provided by applicant): Proteolytic antibodies are a novel therapeutic modality potentially impacting current antibody- based therapy. The ultimate goal of this project is to develop potent proteolytic human monoclonal antibodies (mAb) against beta Amyloids (Ab) for treatment of Alzheimer's disease. To achieve the objective, a novel approach was developed to produce a yeast intracellular human monoclonal antibody library (iHuMab) that can create 1016 possible unique antibodies. A (beta amyloid) specific monoclonal antibodies with protease activity will be screened using iHuMAbeta library and highly specific and tightly regulated multi-reporter system. At the end of phase I, we expect up to 10 unique A specific proteolytic antibodies will be expressed, purified and characterized. Their A40 specific hydrolysis, binding affinity and neutralization capacity will be validated. In phase II A specific antibodies having the highest affinity and protease activity will be produced in large scale quantities for further testing of A40 neutralization effects in mouse models of Alzhemer's disease. Also in Phase II, the most promising molecules would be subjected to pre-clinical evaluation in animal models, pursuant to submission of an IND application for clinical trials. PUBLIC HEALTH RELEVANCE: Therapeutic monoclonal antibodies are one of the fastest growing biotechnology sectors showing marked success for the treatment of various diseases. Proteolytic antibodies are a potential novel therapeutic that could provide a comparable or better benefit but requiring reduced dosages, therefore reducing the cost while increase efficacy. In this project, iHuMAbeta technology platform is developed to identify human proteolytic antibodies against beta-amyloid peptide, a promising target for the treatment of Alzheimer's Disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2011 ( Subtotal = $282,519 )
2011	2011	ABZYME THERAPEUTICS LLC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Aging Research	000	1	6/13/2011	NEW	$282,519
														Subtotal = $282,519

Grand Total All Awards = $282,519

Top

All Categories

About

Search

Reports

Data Submission

Award Information

HUMAN PROTEOLYTIC BETA-AMYLOID SPECIFIC ANTIBODIES FOR TREATMENT OF ALZHEIMERS DI

Award Number: R43AG039892

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2011

PERIOD OF PERFORMANCE END DATE: 05/31/2012

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer